Close Menu

Shares of Benitec Biopharma resumed trading on the Australian Stock Exchange this week after the company announced that it had closed a A$800,000 ($821,760) private placement that it said would give it resources enough to fund a clinical trial of its recently reacquired hepatitis C drug candidate.

Trading of Benitec’s stock had been suspended for about week in advance of the disclosure.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The US Patent and Trademark Office is opening another interference proceeding in the CRISPR patent fight.

The Japan News writes that Japan needs to seize the opportunity to ensure that a wide number of people benefit from personalized cancer treatments.

There's increasing genetic evidence that a number of ancient hominins may have contributed to the human gene pool, according to Discover's The Crux blog.

In Cell this week: messenger RNA expression and translation, RNA localization atlas, and more.